Mitsubishi drops 14% after recalling products approved with falsified data

Shares in Japanese drugmaker Mitsubishi Tanabe Pharma plunged 14% - their biggest one-day drop in 21 years - after the company said it  would recall two blood products because allergy study data on one of  them had been falsified during pilot production as part of the  application for approval. The Medway human serum albumin 5% and 25%  injection products were authorized in October 2007 and were launched in  the Japanese market last May. At the end of last year, Mitsubishi's  development partner Bipha Corp, informed the firm that it had  intentionally exchanged some of the authentic test data with irrelevant  findings when preparing the marketing application submission. The  exchange involved data on the passive cutaneous anaphylaxis reaction  test in rats for validation of commercial-scale manufacture.